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ABSTRACT
Rottlerin, isolated from a medicinal plant Mallotus phillippinensis, has been 
demonstrated to inhibit cellular growth and induce cytoxicity in glioblastoma cell 
lines through inhibition of calmodulin-dependent protein kinase III. Emerging 
evidence suggests that rottlerin exerts its antitumor activity as a protein kinase C 
inhibitor. Although further studies revealed that rottlerin regulated multiple signaling 
pathways to suppress tumor cell growth, the exact molecular insight on rottlerin-
mediated tumor inhibition is not fully elucidated. In the current study, we determine 
the function of rottlerin on glioma cell growth, apoptosis, cell cycle, migration and 
invasion. We found that rottlerin inhibited cell growth, migration, invasion, but 
induced apoptosis and cell cycle arrest. Mechanistically, the expression of Cdc20 
oncoprotein was measured by the RT-PCR and Western blot analysis in glioma cells 
treated with rottlerin. We observed that rottlerin significantly inhibited the expression 
of Cdc20 in glioma cells, implying that Cdc20 could be a novel target of rottlerin. 
In line with this, over-expression of Cdc20 decreased rottlerin-induced cell growth 
inhibition and apoptosis, whereas down-regulation of Cdc20 by its shRNA promotes 
rottlerin-induced anti-tumor activity. Our findings indicted that rottlerin could exert 
its tumor suppressive function by inhibiting Cdc20 pathway which is constitutively 
active in glioma cells. Therefore, down-regulation of Cdc20 by rottlerin could be a 
promising therapeutic strategy for the treatment of glioma.
INTRODUCTION
Cerebral glioma is the most common brain tumor, 
which is one of the top ten malignant tumors in human [1]. 
Among primary malignant brain tumors, 80 percent tumors 
are malignant gliomas (MGs). Glioblastoma multiforme 
(GBM) accounts for more than half of MG cases [2]. MGs 
have been reported to be associated with high morbidity 
and mortality [3]. Multiple studies have demonstrated 
that many potential risk factors could contribute to brain 
tumors, although detailed explanation how these factors 
are involved in brain tumorigenesis is unclear. The most 
important factors of brain tumor development include 
exposure to ionizing radiation, and history of allergy or 
atopic disease [4]. Surgery is often difficult to remove 
entire brain tumor and chemotherapeutic drugs cannot 
pass the blood-brain barrier [5]. Therefore, current 
combinations of surgical resection, radiation therapy and 
chemotherapy regimens fail to significantly improve long-
term patient survival for these brain cancers [6]. Thus, it 
is pivotal to discover the new therapeutic agents for the 
treatment of glioma.
Rottlerin, also called mallotoxin, is isolated 
from plant Mallotus phillippinensis [7]. Initial studies 
identified that rottlerin is an inhibitor of PKCδ (protein 
kinase C δ) [8]. In recent years, increasing evidence 
implicated that rottlerin exhibited its anti-tumor activity 
through inhibition of cell proliferation [9] and migration 
[10], induction of apoptosis [11] and cell cycle arrest [12] 
in a variety of human cancer cells. Interestingly, rottlerin 
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was discovered to induce autophagy and apoptotic 
cell death through PKCδ-independent pathway [13]. 
Li et al. also found that rottlerin induced proapoptotic 
endoplasmic reticulum stress via PKCδ-independent 
pathway in human colon cancer cells [14]. Similarly, 
rottlerin induced apoptosis through upregulation of 
DR5 (death receptor 5) via PKCδ-independent pathway 
in human malignant tumor cells [14]. Mechanistically, 
rottlerin was reported to inhibit the NF-κB (nuclear factor 
kappa B)/cyclin D1 cascade in breast cancer cells [15]. 
Moreover, Ohno et al. found that rottlerin stimulates 
apoptosis in pancreatic cancer cells through disrupting 
the interactions between prosurvival Bcl-2 proteins and 
proapoptotic BH3-only proteins [16]. Although multiple 
studies identified the molecular insight onto rottlerin-
induced tumor suppression, the underlying mechanisms 
are still elusive.
Ubiquitination by the UPS (ubiquitin proteasome 
system) controls cell cycle progression via protein 
degradation [17]. APC/C (anaphase promoting 
complex/C) is a multi-subunit E3 ubiquitin ligase, 
which forms APCCdc20 to exert its biological functions 
largely through targeting its downstream substrates for 
ubiquitination and subsequent degradation [18–20]. 
Emerging evidence has demonstrated that Cdc20 
(cell division cycle 20) has an oncogenic function in 
tumorigenesis [18]. Overexpression of Cdc20 has been 
identified in a broad spectrum of human cancers and is 
associated with poor prognosis in various types of cancers 
[21–23]. For example, overexpression of Cdc20 was 
observed in glioblastomas, whereas Cdc20 was under-
expressed in low-grade gliomas [24]. Furthermore, Cdc20 
level was significantly correlated with glioma grade and 
survival time [25]. Mechanistically, it has been found 
that APC/C (Cdc20) controls the ubiquitin-mediated 
degradation of p21 in prometaphase [26]. In addition, 
one study reported that Cdc20-mediated degradation 
of conductin regulated Wnt/beta-catenin signaling for 
maximal activity during G1/S [27]. Moreover, Cdc20 has 
been identified to be negatively regulated by p53 [28]. 
These reports indicated that Cdc20 could be a potential 
therapeutic target for combating human cancers.
In the current study, we investigated whether 
Cdc20 plays an important role in regulation of cell 
growth, apoptosis, cell cycle, migration and invasion in 
glioma cells. Moreover, we explored whether rottlerin 
could inhibit the expression of Cdc20 in glioma cells. 
Furthermore, we determined whether rottlerin exerts its 
anticancer function via inactivation of Cdc20 in glioma 
cells. We found that rottlerin suppressed cell growth 
and induced apoptosis and cell cycle arrest in glioma 
cell lines. We also demonstrated that rottlerin could 
down-regulate the expression of Cdc20, leading to 
anti-tumor activity in glioma cells. Therefore, rottlerin 
could be a potential efficient agent to inhibit Cdc20 in 
glioma.
RESULTS
Rottlerin inhibited glioma cell proliferation
Rottlerin has been reported to exhibit anti-proliferation 
in human cancer cells. To determine whether rottlerin could 
inhibit the glioma cells growth, MTT assay was performed 
in U251 and SNB19 glioma cells treated with different 
concentrations of rottlerin for 48 h and 72 h. We observed 
that rottlerin treatment caused cell growth inhibition in 
the time- and dose- dependent manners in glioma cells 
(Figure 1A). Our MTT results have clearly demonstrated 
that rottlerin inhibited cell proliferation in glioma cells.
Rottlerin induced cell apoptosis in glima cells
Next, we determine whether rottlerin could trigger 
cell apoptosis in glioma cells, PI-FITC-annexin assay 
was conducted in U251 and SNB19 glioma cells treated 
with 2 µM and 4 µM rottlerin for 48 hours. We found 
that 2 µM and 4 µM rottlerin induced cell apoptosis 
from 4.15% to 14.01%, to 22.07%, respectively, in U251 
cells (Figure 1B). Similarly, 4 µM rottlerin treatments 
led to cell apoptosis from 6.33% to 14.23% in SNB19 
cells (Figure 1B). These results indicated that rottlerin 
stimulated cell apoptosis in glioma cells.
Rottlerin induced cell cycle arrest in glioma cells
To dissect whether rottlerin treatment could arrest 
cell cycle in glioma cells, cell cycle analysis with PI 
staining and flow cytometry was used to test the cell 
cycle in U251 and SNB19 cells after 2 μM and 4 μM 
rottlerin treatments for 48 h. We found that it has a 
typical G0/G1 cycle arrest in the rottlerin-treated glioma 
cells (Figure 1C). Specifically, 2 µM and 4 µM rottlerin 
led to G1 cell population from 59% to 77% to 82%, 
respectively, in U251 cells (Figure 1C). Similarly, 2 µM 
and 4 µM rottlerin treatments caused G1 cell population 
from 65.7% to 73.4% to 81%, respectively, in SNB19 cells 
(Figure 1C). These findings suggest that rottlerin induced 
G1 cell cycle arrest in glioma cells.
Rottlerin inhibited cell migration and invasion
To explore whether rottlerin plays a key role in 
regulation of motility of glioma cells, invasion assay was 
performed in glioma cells treated with rottlerin for 20 
hours. We found that rottlerin significantly retarded the 
penetration of glioma cells through the Matrigel-coated 
membrane in a dose-dependent manner, suggesting 
that rottlerin inhibited cell invasion in glioma cells 
(Figure 2A). To further investigate the inhibition of 
migration in glioma cells by rottlerin, scratch assay was 
used to detect the migratory activity in glioma cells after 
rottlerin treatment. The results from our wound healing 
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assay showed that rottlerin remarkably suppressed cell 
migration in a dose-dependent manner in both glioma 
cell lines (Figure 2B). Altogether, rottlerin inhibited cell 
motility in glioma cells.
Rottlerin decreased Cdc20 expression
Emerging evidence has demonstrated that Cdc20 
plays an oncogenic role in the development and progression 
of human cancers [18]. Further studies revealed that 
targeting Cdc20 could be a novel therapeutic approach 
in human cancers [29]. Therefore, we explored whether 
rottlerin could down-regulate the expression of Cdc20 in 
glioma cells. RT-PCR and Western blotting analysis were 
used to detect the expression of Cdc20 in glioma cells 
after rottlerin treatment for 72 hours. Our RT-PCR results 
showed that Cdc20 mRNA level was down-regulated by 
rottlerin in U251 and SNB19 cells (Figure 3A). Moreover, 
our Western blotting analysis revealed that rottlerin 
significantly decreased Cdc20 protein levels in glioma 
cells (Figure 3B and 3C). Importantly, we also found that 
p21, one of Cdc20 targets, was increased in both glioma 
Figure 1: Effect of Rottlerin on cell growth, apoptosis, and cell arrest. (A) MTT assay was used to detect the cell growth in 
glioma cells treated with rottlerin. *P < 0.05, compared to the control. (B) Cell apoptosis was conducted by FACS in glioma cells treated 
with rottlerin. (C) Cell cycle analysis was determined by Flow cytometry in rottlerin-treated glioma cells.
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cells after rottlerin treatment (Figure 3B and 3C). Our 
findings demonstrated that rottlerin could be a potential 
inhibitor of Cdc20 in glioma cells.
Over-expression of Cdc20 reversed the anti-
proliferation of rottlerin
To validate the function of Cdc20 in rottlerin-
mediated cell growth inhibition, Cdc20 cDNA or empty 
vector as control was transfected into glioma cells 
followed by rottlerin treatment for 48 hours. We found 
that overexpression of Cdc20 promoted cell growth 
in both glioma cells (Figure 4A). More importantly, 
we observed that Cdc20 overexpression abrogated cell 
growth inhibition induced by rottlerin in glioma cells 
(Figure 4A). These findings indicated that rottlerin exerts 
its anti-proliferation of glioma cells via inhibition of 
Cdc20 in glioma cells.
Over-expression of Cdc20 abrogated anti-
motility of rottlerin in glioma cells
To measure the effect of Cdc20 overexpression on 
cell invasion, Matrigel invasion assay was conducted in 
glioma cells after rottlerin treatment and Cdc20 cDNA 
transfection. We found that overexpression of Cdc20 
significantly enhanced cell invasion in both U251 
cells and SNB19 cells (Figure 4B). Moreover, Cdc20 
overexpression abrogated inhibition of cell invasion 
induced by rottlerin in glioma cells (Figure 4B). To further 
explore whether Cdc20 could control cell motility in 
glioma cell lines, scratch assay was performed in glioma 
Figure 2: Rottlerin inhibited cell migration and invasion in glioma cells. (A) Left panel: The inhibitory effect of rottlerin on glioma 
cell invasion was determined by Transwell chambers assay in U251 cells (Top panel) and SNB19 cells (Bottom panel). Right panel: Quantitative 
results are illustrated for left panel. (B) Left panel: Cell migration was detected using wound healing assay in U251 cells (Top panel) and SNB19 
cells (Bottom panel) after rottlerin treatment. Quantitative results are illustrated for left panel. *P < 0.05, **P < 0.01 vs control.
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cells treated with rottlerin in combination with Cdc20 
cDNA transfection. Our scratch assay showed that over-
expression of Cdc20 promoted the glioma cell migration 
(Figure 5A). Overexpression of Cdc20 reversed the cell 
migration inhibition in rottlerin-treated glioma cells 
(Figure 5A). Importantly, we found that Cdc20 cDNA 
transfection upregulated Cdc20 expression in glioma 
cells (Figure 5B). Additionally, Cdc20 overexpression 
abrogated the inhibition of Cdc20 in glioma cells treated 
with rottlerin (Figure 5B). Consistently, p21 expression 
is downregulated in Cdc20-transfected glioma cells 
(Figure 5B). Similarly, Cdc20 cDNA transfection reversed 
the upregulation of p21 by rottlerin in both glioma cells 
(Figure 5B). Our data suggested that rottlerin inhibited cell 
motility partly through inhibition of Cdc20 in glioma cells. 
Down-regulation of Cdc20 by its shRNA 
promoted rottlerin-induced antitumor activity
To further determine the role of Cdc20 in rottlerin-
mediated tumor suppressive activity, we depleted Cdc20 
by its shRNA in glioma cells. We found that down-
regulation of Cdc20 inhibited cell growth in both glioma 
cells (Figure 6A). Moreover, depletion of Cdc20 enhanced 
cell growth inhibition induced by rottlerin in glioma cells 
(Figure 6A). We also observed that down-regulation of 
Cdc20 triggered cell apoptosis in glioma cells (Figure 6B). 
Cdc20 shRNA treatment led to more apoptotic cells 
induced by rottlerin compared with rottlerin alone or Cdc20 
shRNA transfection alone in glioma cells (Figure 6B). Our 
invasion assay showed that depletion of Cdc20 suppressed 
Figure 3: Rottlerin downregulated Cdc20 expression at RNA and protein levels. (A) The mRNA level of Cdc20 was measured 
using RT-PCR in glioma cells treated with rottlerin. *P < 0.05, **P < 0.01 vs control. (B) The expression of Cdc20 and p21 was determined 
by Western blotting analysis in U251 and SNB19 cells after rottlerin treatment. (C) Quantitative results are illustrated for left panel. 
*P < 0.05, **P < 0.01, compared to the control.
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glioma cell invasion (Figure 6C). Notably, Cdc20 shRNA 
enhanced cell invasion inhibition in rottlerin-treated glioma 
cells (Figure 6C). In line with this, depletion of Cdc20 
retarded the cell migration in both U251 and SNB19 
cells (Figure 7A). Furthermore, Cdc20 shRNA promoted 
inhibition of migration induced by rottlerin in glioma cells 
(Figure 7A). Our Western blotting analysis demonstrated 
that Cdc20 shRNA enhanced rottlerin-mediated inhibition 
of Cdc20 in glioma cells (Figure 7B). Consistently, Cdc20 
shRNA promoted rottlerin-induced p21 level in both 
glioma cells (Figure 7B).
DISCUSSION
Rottlerin increased HO-1 (heme oxygenase-1) 
expression via ROS (reactive oxygen species) pathway 
in human colon cancer cells [30]. Rottlerin was also 
exhibited its anti-angiogenesis function via inhibition 
of human microvascular endothelial cell proliferation 
and tube formation on Matrigel [31]. Moreover, rottlerin 
was reported to enhance IL-1β (interleukin-1β)-induced 
COX-2 (cyclooxygenase-2) expression via activation of 
p38 MAPK (mitogen-activated protein kinases) in breast 
cancer cells [32]. Lim et al found that rottlerin induced 
apoptosis via upregulation of NAG-1 through ERK 
(extracellular signal regulated kinase) and p38 MAPK 
pathway in colon cancer cells [32]. Furthermore, rottlerin 
inhibited PI3K (phosphoinositide 3-kinase)/Akt/mTOR 
(mammalian target of rapamycin) pathway, leading to 
autophagy and apoptosis in pancreatic cancer stem cells 
[33] and prostate cancer cells [34]. Lu et al. reported that 
rottlerin induced LRP6 (LDL-receptor related protein 6) 
degradation and inhibited both Wnt/β-catherin and 
mTORC1 signaling in prostate and breast cancer cells 
[35]. Recently, it has been reported that rottlerin inhibited 
pancreatic tumor growth in nude mice [36]. Notably, 
rottlerin suppressed cell growth via the dual inhibition 
of ERK and NF-κB and downregulation of Cyclin D1 in 
melanoma cells [37]. In the present study, we identified 
that rottlerin inhibited Cdc20 expression, resulting in 
inhibition of tumorigenesis in glioma.
Recently, Cdc20 was reported to be a key factor 
in maintaining tumorigenic glioma tumor initiating cells 
through degradation of p21 and regulation of Cdc25C 
(cell division cycle 25C), c-Myc, and Survivin [38]. In 
support of this concept, another study demonstrated that 
Cdc20 drives invasiveness and self-renewal in patient 
tumor-derived GSCs (glioblastoma stem-like cells) 
through pluripotenty related transcription factor SOX2 
[39]. Moreover, using an orthotopic xenograft model 
overexpression of Cdc20 enhanced the GSCs to generate 
brain tumors, whereas depletion of Cdc20 retarded the 
Figure 4: The effect of Cdc20 overexpression on cell growth and invasion. (A) MTT assay was used to detect the effect 
of Cdc20 overexpression in combination with rottlerin treatment on glioma cell proliferation. Control: pcDNA 3.1 treatment; Rottlerin: 
2 µM rottlerin; cDNA: Cdc20 cDNA; Both: rottlerin + Cdc20 cDNA. *P < 0.05, **P < 0.01, compared with control; #P < 0.05 compared 
with rottlerin treatment or Cdc20 cDNA transfection. (B) Left panel, Invasion assay was performed in glioma cells after Cdc20 cDNA 
transfection and rottlerin treatment. Right panel, Quantitative results are illustrated for left panel.
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GSCs to develop brain tumors [39]. Strikingly, it has 
been reported that Cdc20 induced the proliferation of 
primary glial progenitor cells [40]. Some studies showed 
that rottlerin inhibited cancer cell growth and induced 
apoptosis in a variety of human cancers [13, 14, 41, 42]. 
Moreover, rottlerin could suppress growth of human 
pancreatic tumors in nude mice [43, 44]. We also found 
that overexpression of Cdc20 enhanced glioma cell 
proliferation, whereas depletion of Cdc20 suppressed 
cell growth in glioma cells. Our results further showed 
that Cdc20 overexpression enhanced cell migration and 
invasion in glioma cells, while downregulation of Cdc20 
retarded cell motility. Altogether, Cdc20 plays a pivotal 
role in regulation of cell growth, migration and invasion 
in glioma cells.
Since Cdc20 is identified as an oncoprotein in 
tumorigenesis, inactivation of Cdc20 could be useful for 
the treatment of human cancers. To this end, several Cdc20 
Figure 5: The effect of Cdc20 overexpression on cell migration in glioma cells. (A) Left panel: The wound healing assay was 
conducted to detect the cell migration in glioma cells after Cdc20 cDNA transfection and rottleirn treatment. Right panel: Quantitative 
results are illustrated for left panel. Control: pcDNA 3.1 treatment; Rottlerin: 2 µM rottlerin; cDNA: Cdc20 cDNA; Both: rottlerin + Cdc20 
cDNA. *P < 0.05, **P < 0.01, compared with control; #P < 0.05 compared with rottlerin treatment or Cdc20 cDNA transfection. (B) Left 
panel: The expression of Cdc20 and its target p21 was detected by western blotting in glioma cells with Cdc20 cDNA transfection and 
rottlerin treatment. Right panel: Quantitative results are illustrated for left panel.
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inhibitors have been discovered. For example, TAME 
(tosyl-L-arginine methyl ester) reduced Cdc20 association 
with the APC and subsequent inhibited APC E3 ligase 
activity [45]. Moreover, pro-TAME with cell permeable 
activity disrupted the APC-Cdc20/Cdh1 interaction to 
reduce APC activation, leading to cell death in multiple 
cancer cell lines [45]. Notably, apcin (APC inhibitor) binds 
Cdc20 and prevents substrate recognition and competitively 
suppresses the ubiquitination of Cdc20 substrates [46]. 
Strikingly, apcin and pro-TAME synergized to enhance 
the mitotic fraction in human cancer cell lines [46]. In 
addition, compound 331 was found to be a potential drug 
selectively targeting glioma cells through down-regulation 
of Cdc20 [47]. NAHA, a N-alkylated amino acid-derived 
sulfonamide hydroxamate, inhibited the expression 
of Cdc20 in breast cancer cells [48]. Several natural 
agents were identified to inhibit the Cdc20 expression in 
human cancer cells. withaferin A exerted its anti-cancer 
activity through enhanced degradation of Cdc20 and 
Mad2 [49]. Ganodermanontriol (GDNT), a ganoderma 
Figure 6: The effect of Cdc20 downregulation on cell growth, apoptosis and invasion. (A) MTT assay was used to detect 
the effect of Cdc20 shRNA in combination with rottlerin treatment on glioma cell proliferation. Control: siRNA control; Rottlerin: 2 µM 
rottlerin; shRNA: Cdc20 shRNA; Both: rottlerin + Cdc20 shRNA.*P < 0.05, compared with control; #P < 0.05 compared with rottlerin 
treatment or Cdc20 shRNA. (B) Apoptosis was detected by Flow cytometry in glioma cells with Cdc20 shRNA and rottlerin treatment. 
(C) Invasion assay was performed in glioma cells after Cdc20 shRNA and rottlerin treatment.
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alcohol from medicinal mushroom, inactivated Cdc20 
in breast cancer cells [50]. Genistein, the predominant 
isoflavone in soybean enriched foods, was reported to 
exert its anti-carcinogenic properties through inhibition of 
multiple genes including Cdc20 in primary glioblastoma, 
rhabdomyosarcoma, hepatocellular carcinoma and human 
embryonic carcinoma cells [51]. Moreover, genistein 
controlled Cdc20 expression, leading to regulation of cell 
cycle in breast cancer cells [52]. Here, we identified that 
rottlerin could be a new Cdc20 inhibitor in glioma cells. 
Due to non-toxic nature, inactivation of Cdc20 by rottlerin 
could be a safer strategy for the treatment of glioma. 
Figure 7: The effect of Cdc20 downregulation on cell migration in glioma cells. (A) Left panel: The wound healing assay was 
conducted to detect the cell migration in glioma cells after Cdc20 shRNA and rottlerin treatment. Control: siRNA control; Rottlerin: 2 µM 
rottlerin; shRNA: Cdc20 shRNA; Both: rottlerin + Cdc20 shRNA. Right panel: Quantitative results are illustrated for left panel. *P < 0.05, 
vs control; #P < 0.05 vs Cdc20 shRNA treatment or rottlerin treatment. (B) Left panel: The expression of Cdc20 and its target p21 was 
detected by western blotting in glioma cells with Cdc20 shRNA and rottlerin treatment. Right panel: Quantitative results are illustrated for 
left panel. *P < 0.05, **P < 0.01, compared with control; #P < 0.05 compared with rottlerin treatment or Cdc20 shRNA treatment.
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MATERIALS AND METHODS
Cell culture and experimental regents
Human glioma U251 cells and SNB19 cells were 
cultured in DMEM medium with 10% fetal bovine serum 
and 1% penicillin and streptomycin in a 5% CO2 at 37°C. 
Primary antibodies for Cdc20 (#14866, 1:1000) and 
p21 (#2947, 1:1000) were purchased from Abcam and 
Cell Signaling Technology, respectively. All secondary 
antibodies were purchased from Thermo Scientific. 
Lipofectamine 2000 was purchased from Invitrogen. 
Monoclonal anti-β-actin (A2228, 1:5000), rottlerin (CAS 
number 82-08-6, 85%), and MTT (3-4,5-dimethyl-2-
thiazolyl-2, 5-diphenyl-2-H-tetrazolium bromide) were 
obtained from Sigma-Aldrich (St.Louis, MO).
MTT assay
Cells were seeded in 96-well plate at a density of 
5 × 103 cells/well in a volume of 100 μl per well for 24 h 
and treated with different concentrations of rottlerin. After 
48 h and 72 h, 10 μl MTT solution (0.5 mg/ml) was added 
to each well, and the plates were incubated for 4 h at 37°C 
with 5% CO2. Then, the liquid supernatant was removed 
and 100 μl DMSO was added in each well. The absorption 
was measured at 490 nm on the Multimode Reader of 
SpectraMax M5 (Moleucular Devices, US).
Cell apoptosis assay
Cells were seeded at a density of 2 × 105 cells/well 
in 6-well plate with different concentration of rottlerin. 
After 48 h, cells were harvested and washed with PBS, 
cells were suspended with 500 μl binding buffer with 5 μl 
FITC-conjugated anti-Annexin V antibody and 5 μl PI 
(Propidium iodide), and then analyzed with a FACScalibur 
flow cytometer (BD, USA).
Cell cycle analysis
Cells were cultured in six-well plate at a density 
of 2 × 105 cells/well overnight and treated with various 
concentration of rottlerin. After 48 h, cells were harvested 
and washed with PBS, and suspended with 70% cold 
alcohol for overnight in 4°C icebox. Then, cells were 
washed and suspended with 500 μl PBS. Then incubated 
with 100 μg/ml RNase and 50 mg/ml PI (Propidium 
iodide) at 37°C and then analyzed the cell cycle with a 
FACScalibur flow cytometer (BD, USA).
Cell scratch assay
Cells were seeded in 6-well plate for overnight and 
reached almost 100% confluence. Then scratch the cells 
with a sterile 20 μl pipette tip. Wash the detached cells 
with PBS and incubate with different concentrations of 
rottlerin. The scratch was photographed with Box-Type 
Fluorescence Imaging Device (FSX100, OLYMPUS) at 
0 h and 20 h.
Cell invasion assay
Cell invasion assay was used to determine the 
invasive activity of glioma cells treated with rottlerin 
or Cdc20 cDNA or shRNA. Cells tranfected with 
Cdc20 cDNA or shRNA incubated with rottlerin or not 
with 200 μl serum-free medium in the up camber with 
Matrigel. Then added 500 μl DMEM medium with 10% 
FBS. The cells were incubated for 20 h at 37°C with 5% 
CO2 and then strained with Giemsa and photographed 
with Box-Type Fluorescence Imaging Device (FSX100, 
OLYMPUS).
Quantitative real-time reverse transcription-
PCR analysis
The total RNA was extracted with Trizol (Invitrogen, 
Carlsbad, CA) and reversed-transcribed into cDNA by 
RevertAid First Strand cDNA Synthesis Kit. PCR were 
performed using Power SYBR Green PCR Master Mix 
and the results were calculated by 2-⊿⊿Ct method. The 
primers used in the PCR reaction are: Cdc20, forward 
primer (5′- GAC CAC TCC TAG CAA ACC TGG -3′) and 
reverse primer (5′-GGG CGT CTG GCT GTT TTC A-3′); 
GAPDH, forward primer (5′- ACC CAG AAG ACT GTG 
GAT GG -3′) and reverse primer (5′- CAG TGA GCT TCC 
CGT TCA G- 3′).
Western blotting analysis
The harvested cells were washed by PBS and 
lysed with protein lysis buffer. The concentrations of the 
proteins were tested by BCA Protein Assay kit (Thermo 
Scientific, MA). Same amount of protein samples 
were separated by electrophoresis in Sodium Dodecyl 
Sulfonate (SDS)-polyacrylamide gel and then transferred 
onto a Polyvinylidene Fluoride (PVDF) membrane, and 
then incubated with primary antibody at 4°C overnight. 
After washed with TBST for three times and incubated 
with second antibody at room temperature for one 
hour. Then the expression of protein was detected by 
electrochemiluminescence (ECL) assay [53].
Transfection
Cells were seeded into 6-well plates and transfected 
with Cdc20 cDNA or Cdc20 shRNA or empty vector using 
lipofectamine 2000 following the instruction’s protocol. 
After the transfection, the cells were subjected to further 
analysis as described under the results sections.
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Statistical analysis
All statistical analyses were conducted using 
GraphPad Prism 4.0 (Graph Pad Software, La Jolla, CA). 
Student’s t-test was performed to evaluate statistical 
significance. P < 0.05 was considered as statistically 
significant.
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